Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDiaceutics Regulatory News (DXRX)

Share Price Information for Diaceutics (DXRX)

Share Price is delayed by 15 minutes
Get Live Data
141.50    0.00 (0.00%)
Bid:
140.00
Ask:
143.00
Spread: 3.00 (2.143%)
Market Cap: £119.75m
DXRX Live PriceLast checked at - London Stock Exchange

Intraday Diaceutics Share Chart

Investor Presentation

21 Feb 2022 07:00

RNS Number : 1842C
Diaceutics PLC
21 February 2022
 

21 February 2022

Diaceutics PLC

("Diaceutics" or the "Group" or the "Company")

Investor Presentation

 

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces that CEO Peter Keeling and incoming CFO Nick Roberts will provide a live presentation relating to the Company's audited results for the year ended 31 December 2021 via the Investor Meet Company platform on 23 March 2022 at 1pm.

 

The presentation is open to all existing and potential shareholders and registration can be completed via the following link:

 

https://www.investormeetcompany.com/diaceutics-plc/register-investor.

 

Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

 

Investors who already follow Diaceutics on the Investor Meet Company platform will automatically be invited.

 

Enquiries:

Diaceutics PLC 

Peter Keeling, Chief Executive Officer

 

Stifel Nicolaus Europe Limited (Nomad & Broker)

Ben Maddison

Stewart Wallace

Nick Adams

 

Alma PR

Caroline Forde

Kieran Breheny

Matthew Young

 Via Alma PR

 

Tel: +44 (0)20 7710 7600

 

 

Tel: +44(0)20 3405 0205

diaceutics@almapr.co.uk

 

 

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®. 

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAQVLFFLLLFBBL
Date   Source Headline
1st Jun 20262:00 pmRNSPDMR Shareholding/Share Incentive Plan & TVRs
29th May 20262:00 pmRNSNotice of AGM & Posting of Annual Report
26th May 20267:00 amRNSFinal Results
13th May 20267:00 amRNSNotice of Results
12th May 20262:00 pmRNSHolding(s) in Company
5th May 20267:00 amRNSPDMR Shareholding/Share Incentive Plan and TVRs
16th Apr 20261:11 pmRNSRelated Party Transaction - Lease Extension
7th Apr 20267:00 amRNSBlock Listing Return
1st Apr 202611:59 amRNSPDMR Shareholding/SIP & Total Voting Rights
3rd Mar 202610:56 amRNSPDMR Shareholding/Share Incentive Plan and TVRs
3rd Feb 20268:01 amRNSPDMR Shareholding/Share Incentive Plan & TVR
15th Jan 20267:00 amRNSFull Year 2025 Trading Update
23rd Dec 20257:00 amRNSPDMR Shareholding/SIP & Total Voting Rights
23rd Dec 20257:00 amRNSPDMR Shareholding/SIP & Total Voting Rights
28th Nov 202511:53 amRNSPDMR Shareholding/SIP & Total Voting Rights
4th Nov 20257:00 amRNSPDMR Shareholding/Share Incentive Plan and TVR
7th Oct 20257:00 amRNSBlock listing Interim Review
1st Oct 202511:40 amRNSPDMR Shareholding/Share Incentive Plan and TVR
23rd Sep 20257:00 amRNSH1 2025 Results
11th Sep 20257:00 amRNSNotice of Results
9th Sep 202510:47 amRNSHolding(s) in Company
2nd Sep 20257:00 amRNSPDMR Shareholding/Share Incentive Plan and TVR
11th Aug 202510:58 amRNSHolding(s) in Company
5th Aug 20257:00 amRNS-RDiaceutics at Canaccord Genuity Growth Conference
30th Jul 20257:00 amRNSPDMR Shareholding/Share Incentive Plan and TVR
29th Jul 20257:00 amRNS-RDiaceutics Announces Key Leadership Appointment
25th Jul 202512:15 pmRNSHolding(s) in Company
23rd Jul 20257:00 amRNSIssue of Share Options / PDMR Shareholdings
22nd Jul 20257:00 amRNS22% Revenue Growth H125 representing 3-yr CAGR 25%
17th Jul 20257:00 amRNS-RExpansion of PMx Commercialization Partnership
30th Jun 20257:00 amRNSPDMR Shareholding/SIP and Total Voting Rights
18th Jun 202512:00 pmRNSResults of AGM
6th Jun 20259:33 amRNSPDMR Shareholding /Share Incentive Plan and TVR
21st May 20255:00 pmRNSNotice of AGM and Posting of Annual Report
15th May 20257:00 amRNSTransaction by Persons Closely Associated to PDMRs
13th May 20257:00 amRNSFY 2024 Results - Strong Revenue Growth
29th Apr 20254:09 pmRNSPDMR Shareholding/Share Incentive Plan and TVR
29th Apr 20257:00 amRNSNotice of Results
7th Apr 202510:33 amRNSBlock Listing Return
3rd Apr 20251:54 pmRNSPDMR Shareholding/Share Incentive Plan and TVR
26th Mar 20257:00 amRNSPMx Promotional Partner Contract Enhancement
6th Mar 20253:16 pmRNSHolding(s) in Company
3rd Mar 20253:00 pmRNSPDMR Shareholding/Share Incentive Plan and TVR
31st Jan 20259:13 amRNSPurchase of Shares and PDMR Shareholding
30th Jan 202511:27 amRNSPDMR Shareholding/Share Incentive Plan
28th Jan 20257:00 amRNSFY 2024 Trading Update - Strong Revenue Growth
14th Jan 20257:00 amRNSDiaceutics Opens US Headquarters
8th Jan 20257:00 amRNSNew Service Launched & First Contract Signed
3rd Jan 20253:39 pmRNSPDMR Dealings & Total Voting Rights
19th Dec 20248:09 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.